News Details

Fourth Quarter 2018 Highlights

• Salesof $715 million grew 4% as reported and 5% in constant currency
• Growth across all end markets, with strong pharmaceutical and TA results
• Strong growth in China and improved U.S. performance; slight decline in Europe
• GAAP EPS of $2.46; non-GAAP EPS increased 14% to $2.87

MILFORD, Mass.--(BUSINESS WIRE)--Jan. 23, 2019-- Waters Corporation (NYSE: WAT)today announced fourth quarter 2018 sales of $715 million, a 4% increase as reported, compared to sales of $687 million for the fourth quarter of 2017. Foreign currency translation negatively impacted sales growth by approximately 1% for the quarter.

On a GAAP basis, diluted earnings per share (EPS) for the fourth quarter of 2018 increased to $2.46, compared to a diluted loss per share of $4.44 for the fourth quarter of 2017, which included a $550 million income tax charge. On a non-GAAP basis, EPS increased 14% to $2.87, compared to $2.51 for the fourth quarter of 2017. A description and reconciliation of GAAP to non-GAAP results appear in the table below and can be found on the Company’s website at http://www.waters.com under the caption “Investors.”

On a GAAP basis, net cash provided by operating activities for the fourth quarter of 2018 was $182 million versus $192 million for the fourth quarter of 2017. On a non-GAAP basis, adjusted free cash flow for the fourth quarter of 2018 was $160 million versus $162 million for the fourth quarter of 2017.

For fiscal year 2018, the Company’s sales were $2,420 million, up 5% as reported, compared to sales of $2,309 million for fiscal year 2017. Foreign currency translation increased sales growth by approximately 1% during fiscal year 2018. On a GAAP basis, EPS for fiscal year 2018 was $7.65, compared to $0.25 for fiscal year 2017. On a non-GAAP basis, and including adjustments in the reconciliation below, EPS increased 11% to $8.29, compared to $7.49 for fiscal year 2017.

On a GAAP basis, net cash provided by operating activities for fiscal year 2018 was $604 million versus $698 million for fiscal year 2017. On a non-GAAP basis, adjusted free cash flow for fiscal year 2018 was $600 million versus $612 million for fiscal year 2017.

Chris O’Connell, Chairman and Chief Executive Officer of Waters Corporation, commented, “We were pleased to end 2018 on a high note, with improving performance in our key market categories, products, and geographies. This fourth quarter improvement was highlighted by strength in our pharmaceutical category, TA product line, and China. We are looking forward to building on this momentum in 2019 and expect to benefit from our new product cycle, headlined by yesterday’s BioAccord system launch.”

Unless otherwise noted, sales growth and decline percentages are presented on an as-reported basis and are the same as the sales growth and decline percentages presented on a constant-currency basis as compared with the same period in the prior year, each of which is detailed in the reconciliation of sales growth rates to constant-currency growth rates below.

During the fourth quarter of 2018, sales into the pharmaceutical market grew 6% as reported and 7% in constant currency, sales into the industrial market grew 1% as reported and 2% in constant currency, and sales into the governmental and academic markets grew 2% as reported and 3% in constant currency. During fiscal year 2018, sales into the pharmaceutical market grew 5% as reported and 4% in constant currency, sales into the industrial market grew 2% as reported and 1% in constant currency, and sales into the governmental and academic markets grew 8% as reported and 7% in constant currency.

During the fourth quarter, recurring revenues, which represent the combination of service and precision chemistries revenues, grew 5% as reported and 6% in constant currency, while instrument system sales grew 3% as reported and 4% in constant currency. For fiscal year 2018, recurring revenues grew 8% as reported and 6% in constant currency, while instrument system sales grew 2% as reported and 1% in constant currency.

Geographically, sales in Asia during the quarter grew 8% as reported and 9% in constant currency, sales in the Americas grew 5% as reported and 6% in constant currency (with U.S. sales growing 5%), and sales in Europe declined 3% as reported and 1% in constant currency. For fiscal year 2018, sales in Asia grew 7% as reported and 6% in constant currency, sales in the Americas grew 3% (with U.S. sales growing 2%), and sales in Europe grew 4% as reported and 1% in constant currency.

First Quarter and Fiscal Year 2019 Financial Outlook

The Company expects full-year 2019 constant currency sales growth in the range of 4% to 6%. As of today, currency translation is expected to decrease full-year sales growth by 1% to 2%. The Company also expects full-year 2019 non-GAAP earnings per fully diluted share in the range of $9.20 to $9.45. Please refer to the table below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the full year.

The Company expects first quarter 2019 constant currency sales growth in the range of 4% to 6%. As of today, currency translation is expected to decrease first quarter sales growth by approximately 2% to 3%. The Company also expects first quarter 2019 non-GAAP earnings per fully diluted share in the range of $1.65 to $1.75. Please refer to the table below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the first quarter.

New $4 Billion Share Repurchase Authorization

Waters Corporation also announced today that its Board of Directors authorized a new share repurchase program. This new program authorizes the purchase of up to $4 billion of the Company’s common stock over a two-year period and replaces the pre-existing program.

Conference Call

Waters Corporation will webcast its fourth quarter 2018 financial results conference call today, January 23, 2019 at 8:00 a.m. Eastern Time. To listen to the call, please visit www.waters.com, choose “Investors,” and click on the “Live Webcast.” A replay will be available through January 30, 2019 at midnight Eastern Time on the same website by webcast and also by phone at 402-220-0191.

About Waters Corporation

Waters Corporation (NYSE: WAT), the world's leading specialty measurement company, has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years. With approximately 7,000 employees worldwide, Waters operates directly in 31 countries, including 15 manufacturing facilities, and with products available in more than 100 countries. For more information, visit www.waters.com.

Non-GAAP Financial Measures

This press release contains financial measures, such as constant currency growth rate, adjusted operating income, adjusted net income, adjusted earnings per diluted share and free cash flow, among others, which are considered “non-GAAP” financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with generally accepted accounting principles (GAAP). The Company’s definition of these non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of Waters Corporation’s historical operating results, comparison to competitors’ operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Waters Corporation’s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

Cautionary Statement

This release may contain “forward-looking” statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words, “feels”, “believes”, “anticipates”, “plans”, “expects”, “intends”, “suggests”, “appears”, “estimates”, “projects”, and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons, including and without limitation, foreign exchange rate fluctuations potentially affecting translation of the Company’s future non-U.S. operating results; the impact on demand for the Company’s products among the Company’s various market sectors from economic, sovereign and political uncertainties, particularly regarding the effect of new or proposed tariff or trade regulations; the effect on the Company’s financial results from the United Kingdom voting to exit the European Union; fluctuations in expenditures by the Company’s customers, in particular large pharmaceutical companies; introduction of competing products by other companies and loss of market share; pressures on prices from competitors and/or customers; regulatory, economic and competitive obstacles to new product introductions; other changes in demand for the Company’s products from the effect of mergers and acquisitions by the Company’s customers; increased regulatory burdens as the Company’s business evolves, especially with respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, among others; impact of the newly enacted tax reform legislation in the U.S.; shifts in taxable income in jurisdictions with different effective tax rates; the outcome of tax examinations or changes in respective country legislation affecting the Company’s effective tax rate; the effect of the adoption of new accounting standards; the ability to access capital, maintain liquidity and service the Company’s debt in volatile market conditions, particularly in the U.S., as a large portion of the Company’s cash is held and operating cash flows are generated outside the U.S.; environmental and logistical obstacles affecting the distribution of products and risks associated with lawsuits and other legal actions, particularly involving claims for infringement of patents and other intellectual property rights. Such factors and others are discussed more fully in the sections entitled “Forward-Looking Statements” and “Risk Factors” of the Company’s annual report on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission, which “Forward-Looking Statements” and “Risk Factors” discussions are incorporated by reference in this release. The forward-looking statements included in this release represent the Company’s estimates or views as of the date of this release and should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this release.

(1) The Company adopted new accounting guidance which requires that an employer disaggregate the service cost component from other components of net benefit cost. As a result of the adoption of this standard, the components of net periodic benefit cost other than the service cost component are included in other income in the consolidated statements of operations and all previous periods have been adjusted accordingly.

(2) In May 2018, the Company's board of directors approved the termination of its frozen U.S. defined benefit pension plans. In December 2018, the Company settled a pension plan obligation by making lump-sum cash payments and purchasing annuity contracts for participants to permanently extinguish the pension plan's obligations. As a result, the Company recorded a $46 million charge, which consisted of a $6 million cash contribution to the plan and a $40 million non-cash charge related to the reversal of unrecognized actuarial losses recorded in accumulated other comprehensive income in the stockholders' equity.

(3) The provision for income taxes for the three and twelve months ended December 31, 2017 included a $550 million estimate for the impact of the enactment of the Tax Cuts and Jobs Act. The provision for income taxes for the three and twelve months ended December 31, 2018 included a $5 million benefit and a $1 million expense, respectively, related to U.S. tax reform. The provisions include: (1) an adjustment to our 2017 year end accrual for the toll charge resulting from federal proposed regulations and other state guidance and (2) the tax that results from the change in foreign currency exchange rates on the earnings taxed on December 31, 2017 under the Tax Cuts and Jobs Act as compared with the foreign currency exchange rates on the date of distribution of assets into the U.S.

(a) The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation's net sales. Constant currency growth rate, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, ignoring the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.

(a) The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation's net sales. Constant currency growth rate, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, ignoring the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.

(a) Selling & administrative expenses include purchased intangibles amortization and litigation provisions. Research & development expenses include acquired in-process research and development.

(b) The purchased intangibles amortization, a non-cash expense, was excluded to be consistent with how management evaluates the performance of its core business against historical operating results and the operating results of competitors over periods of time.

(c) Restructuring costs and certain other items were excluded as the Company believes that the cost to consolidate operations and reduce overhead and certain other income or expense items are not normal and do not represent future ongoing business expenses of a specific function or geographic location of the Company.

(d) In May 2018, the Company's board of directors approved the termination of its frozen U.S. defined benefit pension plans. In December 2018, the Company settled a pension plan obligation by making lump-sum cash payments and purchasing annuity contracts for participants to permanently extinguish the pension plan's obligations. As a result, the Company recorded a $46 million charge, which consisted of a $6 million cash contribution to the plan and a $40 million non-cash charge related to the reversal of unrecognized actuarial losses recorded in accumulated other comprehensive income in the stockholders' equity. The pension expense associated with terminating a frozen defined benefit pension plan was excluded as the Company believes these expenses are not indicative of normal operating costs.

(e) Litigation provisions and settlement gains were excluded as these costs are isolated, unpredictable and not expected to recur regularly.

(f) The provision for income taxes for the three and twelve months ended December 31, 2017 included a $550 million estimate for the impact of the enactment of the Tax Cuts and Jobs Act. The provision for income taxes for the three and twelve months ended December 31, 2018 included a $5 million benefit and a $1 million expense, respectively, related to U.S. tax reform. The provisions include: (1) an adjustment to our 2017 year end accrual for the toll charge resulting from federal proposed regulations and other state guidance and (2) the tax that results from the change in foreign currency exchange rates on the earnings taxed on December 31, 2017 under the Tax Cuts and Jobs Act as compared with the foreign currency exchange rates on the date of distribution of assets into the U.S. The Company believes this expense is not indicative of the Company's normal or future income tax expense.

(g) Certain income tax items were excluded as these non-cash expenses and benefits represent updates in management's assessment of ongoing examinations or other tax items that are not indicative of the Company’s normal or future income tax expense.

(h) The non-cash expense associated with accelerating the vesting of certain stock awards was excluded as the Company believes these expenses are not indicative of normal operating costs.

(i) Acquired in-process research and development was excluded as it relates to milestone payments associated with a licensing arrangement for mass spectrometry that the Company believes is unusual and not indicative of its normal business operations.